Abstract
Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases might modify their medications at the time of COVID-19 vaccination to optimise their immune response and mitigate vaccine side-effects. Immunosuppressed patients in New York state were approved for vaccination on Feb 15,2021,1 soon after the American College of Rheumatology COVID-19 Vaccine Clinical Guidance Task Force issued its first management guidelines on Feb 8, 2021.2 Whether real-world behaviour was aligned with these guidelines is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
